HAVCR2 and neoplasm: In addition, several attempts have been made to investigate the synergistic efficacy of TIM-3 inhibitor combined with chemotherapy or radiotherapy and anti-PD-1/PD-L1 therapy in tumor model mice [139, 142, 143].